ImmunityBio Investors Face May 26 Deadline in Class Action After FDA Flags Misleading Anktiva Claims

Overview

• ImmunityBio faces a federal securities class action in California covering purchases from January 19 to March 24, 2026, with investors able to seek lead‑plaintiff status by May 26.
• The suit followed an FDA Warning Letter that said a TV ad and a podcast about Anktiva were false or misleading, including a claim the drug could cure or prevent all cancer.
• IBRX shares fell about 21% to $7.42 on March 24, 2026 after reports of the FDA letter, a drop that erased roughly $2 billion in market value.
• The complaint names ImmunityBio and Executive Chairman Patrick Soon‑Shiong, alleging he personally made the promotional statements on a nationally broadcast podcast.
• Law firms including Kessler Topaz, Levi & Korsinsky, and Hagens Berman are recruiting shareholders on a contingency basis to seek the lead role and pursue potential recovery.